Addiction

Papers
(The H4-Index of Addiction is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling301
An Addiction series on regional perspectives on addiction‐related problems287
Society for the Study of Addiction Annual Conference 2024140
122
109
The use of financial incentives for smoking cessation in pregnant women: A parallel‐group randomised controlled trial protocol106
Use of cessation products, e‐cigarettes and cigarette cessation outcomes among adults with substance use problems: Results from 2013–2021 (Waves 1–6) of the Population Assessment of Tobacco and Health96
Structure and stability of internet gaming disorder from childhood to late adolescence: A 5‐wave birth cohort study94
Risk of readmission among individuals with cannabis use disorder during a 15‐year cohort study: the impact of socio‐economic factors and psychiatric comorbidity89
Will Australia's tightened prescription system reduce nicotine vaping among young people?83
Commentary on Keyes and Patrick: Changes in psychedelic use in the United States may require changes in our narrative of psychedelic harms79
Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis73
Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness73
Age, period and cohort effects of heavy episodic drinking by sex/gender and socioeconomic position in Canada, 2000–202171
Nicotine strength of e‐liquids used by adult vapers in Great Britain: A population survey 2016 to 202470
Chronic obstructive pulmonary disease in heroin users: An underappreciated issue with clinical ramifications67
The Baltics: Benchmarking alcohol control reform for the European Union and surrounding countries64
Significant changes in preference of illicit drug use in a population of Hanoi, Vietnam—A 6‐year wastewater study (2018–2023)58
ABC‐training as a new intervention for hazardous alcohol drinking: Two proof‐of‐principle randomized pilot studies53
51
Rare but relevant series48
Evaluating the optimal duration of medication treatment for opioid use disorder46
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial44
Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and met42
Estimating recent trends in alcohol sales in the United Kingdom from alcohol duty revenue42
Austin Bradford Hill’s ‘Environment and disease: Association or causation’41
Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data41
Longitudinal associations between substance use problem severity and relative harm perceptions of e‐cigarettes compared with cigarettes: Results from the United States Population Assessment of Tobacco40
Commentary on Stull et al.: Considering person‐specific heterogeneity when modeling time‐varying trends39
Systematic review and meta‐analyses of cytisine to support tobacco cessation38
Quantifying alcohol‐attributable disability‐adjusted life years to others than the drinker in Aotearoa/New Zealand: A modelling study based on administrative data37
Recent decline in Chinese alcohol production and consumption: Potential contributing factors and the role of globally recommended measures37
Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation37
National profile on substance use, substance use‐related problems and policy: The case of Chile37
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial36
The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis36
0.20156383514404